GlassScriptPhysician profile
Alexandra Guillaume
NPI 1396981197
$13,756.02
in general payments reported to CMS, 2019-2025
32 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,183 · 2020: $573 · 2021: $1,477 · 2022: $1,673 · 2023: $1,456 · 2024: $676 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,850.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,730.31 | 2019-2020 | |
| Abbvie INC. | $3,273.35 | 2019-2025 | |
| Janssen Biotech, INC. | $1,000.76 | 2019-2025 | Stelara, Tremfya |
| Regeneron Healthcare Solutions, INC. | $367.52 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $363.94 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $323.18 | 2019-2025 | Entyvio |
| Ferring Pharmaceuticals INC. | $322.07 | 2019-2023 | Rebyota |
| Medtronic, INC. | $293.18 | 2021-2024 | Endoflip |
| Endogastric Solutions, INC | $290.38 | 2021-2024 | Esophyx |
| Intercept Pharmaceuticals, INC. | $234.87 | 2021-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $214.32 | 2019-2023 | Linzess |
| Ardelyx, INC. | $207.05 | 2023-2025 | Ibsrela |
| Laborie Medical Technologies Corp. | $161.89 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.47 | 2022-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $138.72 | 2019-2023 | Dificid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Daiichi Sankyo INC. | $99.85 | 2019-2022 | |
| Lilly USA, LLC | $62.26 | 2025 | Omvoh |
| Steris Corporation | $53.47 | 2019 | |
| Genzyme Corporation | $52.19 | 2022-2024 | |
| Celgene Corporation | $46.10 | 2022-2023 | Zeposia |
| Shire North American Group INC | $43.48 | 2019 | |
| Mallinckrodt Hospital Products INC. | $31.23 | 2025 | Terlivaz |
| Alfasigma USA, INC. | $30.36 | 2020 | |
| Pfizer INC. | $29.39 | 2019 | |
| Redhill Biopharma INC. | $24.94 | 2021 | |
| Nestle Healthcare Nutrition INC. | $24.61 | 2021 | |
| Dova Pharmaceuticals | $15.21 | 2019 | |
| Olympus America INC. | $13.53 | 2019 | |
| Dynavax Technologies Corporation | $12.61 | 2021 | |
| Concordia Pharmaceuticals INC. | $11.89 | 2019 | |
| Napo Pharmaceuticals INC | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Guillaume listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.